Kim Lorence H. 4

What Happened
Kim Lorence, a director of Revolution Medicines (RVMD), was granted equity awards on June 18, 2026. The filing shows two awards: 1,191 restricted stock units (RSUs) and a 3,127-share derivative award (an option), each recorded at $0.00 (no cash paid). The reported dollar value in the filing is $0.00 because these are compensation grants rather than open-market purchases.

Key Details

• Transaction date: June 18, 2026; Filing date: June 23, 2026 (filed one day after the typical 2-business-day Form 4 deadline).
• Awards: 1,191 RSUs (F1) and a 3,127-share derivative award/option (A, derivative).
• Reported price per share: $0.00; reported dollar amount: $0.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnotes: F1 confirms the 1,191 awards are RSUs. F2 states the 3,127-share option vests in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the next Annual Meeting, subject to continued service.

Context
These grants are compensation awards, not purchases or sales, so they do not reflect an open-market trade. The 3,127-share item is a derivative (an option) subject to vesting conditions described in the footnote; it has not been exercised or sold. The filing was submitted one day late relative to the usual two-business-day Form 4 deadline, which is a timeliness note for investors to consider.